South Korea’s MFDS cleared Curocell’s Limcato (anbalcabtagene-autoleucel; anbal-cel) as the first homegrown CAR T therapy for advanced diffuse large B-cell lymphoma. The approval marks a domestic first for a CAR T-cell option within the specified indication. The therapy approval adds to South Korea’s growing CAR T ecosystem and may expand access for patients who need rapid, high-acuity immunotherapy pathways. It also sets a benchmark for subsequent locally developed cell therapies seeking regulatory validation. For Curocell, the milestone elevates the clinical and commercial scaling challenge typical of CAR T logistics, manufacturing consistency, and patient journey design.